Abstract
Microtubules are present in all eukaryotic cells. They are responsible for movement of vesicles within cells, motion of cilia and flagella, and chromosome separation in mitosis. In neurons, microtubules serve as tracks for protein particles and organelles that move up and down the axon. They also can direct proteins for repair of cellular injury. Antitubulin agents, including colchicine, vincristine, vinblastine, and podophyllin, inhibit the construction of microtubules, which accounts for the therapeutic and the toxic actions of these agents.
Similar content being viewed by others
References
Hood RL. Colchicine poisoning. J Emerg Med. 1994;12:171–7.
Borron S, Scherrmann J, Baud F. Markedly altered colchicine kinetics in a fatal intoxication: examination of contributing factors. Human Vet Toxicol. 1996;15:885–90.
Milne ST, Meek PD. Fatal colchicine overdose: report of a case and review of the literature. Am J Emerg Med. 1998;16:603–8.
Nagesh KR, Menezes RG, Rastogi P, Naik NR, Rasquinha JM, Senthilkumaran S, et al. Suicidal plant poisoning with Colchicum autumnale. J Forensic Leg Med. 2011;18:285–7.
Sundov Z, Nincevic Z, Definis-Gojanovic M, Glavina-Durdov M, Jukic I, Hulina N, et al. Fatal colchicine poisoning by accidental ingestion of meadow saffron-case report. Forensic Sci Int. 2005;149:253–6.
Mendis S. Colchicine cardiotoxicity following ingestion of Gloriosa superba tubers. Postgrad Med J. 1989;65:752–5. Pubmed Central PMCID: PMC2429836.
Woodbury D, Fingl E. Analgesic-antipyretics, antiinflammatory agents, and drugs employed in the therapy of gout. In: Goodman L, Gilman A, editors. The pharmacologic basis of therapeutics. 5th ed. New York: Macmillan; 1975. p. 350–5. I.
Stahl N, Weinberger A, Benjamin D, Pinkhas J. Fatal colchicine poisoning in a boy with familial Mediterranean fever. Am J Med Sci. 1979;278:77–81.
Kaplan H. Sarcoid arthritis with a response to colchicine. N Engl J Med. 1960;263:778–81.
Torres M, Furst D. Treatment of Generalized Systemic Sclerosis. Rheum Dis Clin North Am. 1990;16:217–41.
Cohen A, Rubinow A, Anderson J. Colchicine treated cases from 1976 to 1983 compared with cases seen in previous years. Am J Med. 1987;82:1182–90.
Anonymous. Criteria for diagnosis of Behcet’s disease. International Study Group for Behcet’s Disease. Lancet. 1990;335:1078–80.
Sander H, Randal H. Use of colchicine in Behcet’s syndrome. Cutis. 1986;37:344–8.
Seidman P, Fjellner B, Johannesson A. Psoriatic arthritis treated with oral colchicine. J Rheumatol. 1987;14:777–9.
Medsger Jr TA. Treatment of systemic sclerosis. Ann Rheum Dis. 1991;50:877–86.
Naidus R, Rodvein R, Meikle H. Colchicine toxicity- a multisystem disease. Arch Intern Med. 1977;137:394–6.
Russell FE, Gertsch WJ. For those who treat spider or suspected spider bites [letter]. Toxicon. 1983;21:337–9.
Keshenobich D, Varga F, Garica-Tsao G. Colchicine in the treatment of cirrhosis of the liver. N Engl J Med. 1988;318:1709–13.
Kaplan M, Alling D, Zimmerman HJ. A prospective trial for colchicine for primary biliary cirrhosis of the liver. N Engl J Med. 1986;315:1448–54.
von den Driesch P. Sweet’s syndrome (acute febrile neutrophilic dermatosis) [see comments]. J Am Acad Dermatol. 1994;31:535–56. quiz 57–60.
Schnebel BE, Simmons JW. The use of oral colchicine for low-back pain. A double-blind study. Spine. 1988;13:354–7.
Simmons JW, Harris WP, Koulisis CW, Kimmich SJ. Intravenous colchicine for low-back pain: a double-blind study. Spine. 1990;15:716–7.
Chyka PA, Seger D, Krenzelok EP, Vale JA, American Academy of Clinical T, European Association of Poisons C, et al. Position paper: single-dose activated charcoal. Clin Toxicol. 2005;43:61–87.
Centers for Disease C, Prevention. Deaths from intravenous colchicine resulting from a compounding pharmacy error – Oregon and Washington, 2007. MMWR – Morb Mortal Wkly Rep. 2007;56:1050–2.
Sussman JS, Brozena SC, Skop N, Korecka M, Shaw LM. Accidental intravenous colchicine poisoning. Ther Drug Monit. 2004;26:688–92.
Wallace S, Singer J. Review: systemic toxicity associated with the intravenous administration of colchicine-Guidelines for use. J Rheumatol. 1988;15:495–9.
Finkelstein Y, Aks SE, Hutson JR, Juurlink DN, Nguyen P, Dubnov-Raz G, et al. Colchicine poisoning: the dark side of an ancient drug. Clin Toxicol (Phila). 2010;48:407–14.
Ben-Chetrit E, Levy M. Colchicine: 1998 update. Semin Arthritis Rheum. 1998;28:48–59.
Folpini A, Furfori P. Colchicine toxicity – clinical features and treatment. Massive overdose case report. J Toxicol – Clin Toxicol. 1995;33:71–7.
Wallace SL, Omokoku B, Ertel NH. Colchicine plasma levels. Implications as to pharmacology and mechanism of action. Am J Med. 1970;48:443–8.
Terkeltaub RA, Furst DE, Digiacinto JL, Kook KA, Davis MW. Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors. Arthritis Rheum. 2011;63:2226–37.
Atasoyu EM, Evrenkaya TR, Solmazgul E. Possible colchicine rhabdomyolysis in a fluvastatin-treated patient. Ann Pharmacother. 2005;39:1368–9.
Baker SK, Goodwin S, Sur M, Tarnopolsky MA. Cytoskeletal myotoxicity from simvastatin and colchicine. Muscle Nerve. 2004;30:799–802.
Carral J, Milne V, Underberg A. Rhabdomyolysis in a patient taking colchicine and rosuvastatin. J Clin Lipidol. 2014;8:352–3.
Justiniano M, Dold S, Espinoza LR. Rapid onset of muscle weakness (rhabdomyolysis) associated with the combined use of simvastatin and colchicine. JCR: J Clin Rheumatol. 2007;13:266–8.
Terkeltaub RA, Furst DE, Bennett K, Kook KA, Crockett R, Davis MW. High versus low dosing of oral colchicine for early acute gout flare: twenty-four–hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheumat. 2010;62:1060–8.
Terkeltaub RA. Colchicine update: 2008. Semin Arthritis Rheumat. 2009;38:411–9.
Zhou S, Yung Chan S, Cher Goh B, Chan E, Duan W, Huang M, et al. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet. 2005;44:279–304.
Lodish H, Berk A, Zipursky SL, et al. Microtubules and cellular movement. In: Berk A, Zipursky SL, editors. Molecular cell biology. 4th ed. New York: Freeman; 1999. p. 795–897.
Jordan A, Hadfield J, Lawrence N, McGown A. Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle. Med Res Rev. 1998;18:259–96.
Panda D, Jordan M, Chu K, Wilson L. Differential effects of vinblastine on polymerization and dynamics at opposite microtubule ends. J Biol Chem. 1996;271:29807–12.
Chang Y. Mechanism of action of colchicine III Antiinflammatory effects of colchicine compared with phenylbutazone and indomethacin. Arthritis Rheum. 1975;18:493–6.
Spilberg I. Mechanism of action of colchicine in acute urate crystal-induced arthritis. J Clin Invest. 1979;64:775–80.
Baum J, Meyerowitz S. Colchicine: Its use as a suicidal drug by females. J Rheumatol. 1980;7:124–7.
Wells S, Anderson D. Colchicine toxicity: a case report. Vet Hum Toxicol. 1989;31:313–6.
Murray SS, Kramlinger KG, McMichan JC, Mohr DN. Acute toxicity after excessive ingestion of colchicine. Mayo Clin Proc. 1983;58:528–32.
Ferguson F, Colchicine I. General pharmacology. J Pharmacol Exp Ther. 1952;106:261–70.
Hill R, Spragg R, Wedel M. Adult respiratory distress syndrome associated with colchicine intoxication. Ann Intern Med. 1975;83:523.
Sauder P, Kopferschmitt J, Jaeger A, Mantz JM. Haemodynamic studies in eight cases of acute colchicine poisoning. Hum Toxicol. 1983;2:169–73.
Mullins M, Carrico E, Horowitz B. Fatal cardiovascular collapse following acute colchicine ingestion. J Toxicol Clin Toxicol. 2000;38:51–4.
Heath D, Palmer J, Aurbach G. The hypocalcemic action of colchicine. Endocrinology. 1972;90:1589–93.
Kuncl RW, Duncan G, Watson D, Alderson K, Rogawski MA, Peper M. Colchicine myopathy and neuropathy. N Engl J Med. 1987;316:1562–8.
Neuss M. McCallum Rea. Long-term colchicine administration leading to colchicine toxicity and death. Arthritis Rheum. 1986;29:448–9.
Ellwood MG, Robb GH. Self-poisoning with colchicine. Postgrad Med J. 1971;47:129–31.
Gooneratne BW. Massive generalized alopecia after poisoning by Gloriosa superba. Br Med J. 1966;5494:1023–4.
Stanley MW, Taurog JD, Snover DC. Fatal colchicine toxicity: report of a case. Clin Exp Rheumatol. 1984;2:167–71.
Critchley J, Critchley L, Yeung E. Granuloctye-colony stimulating factor in the treatment of colchicine poisoning. Hum Exp Toxicol. 1997;16:229–32.
Harris R, Marx G. Colchicine-induced bone marrow suppression: treatment with granulocyte colony stimulating factor. J Emerg Med. 2000;18:435–40.
Wolff J, Capraro H. Colchicine binding to antibodies. J Biol Chem. 1980;255:7144–8.
Terrien N, Urtizberea M, Schermann J. Reversal of advanced colchicine toxicity in mice with goat colchicine-specific antibodies. Toxicol Appl Pharmacol. 1990;104:504–10.
Baud F. Sabourand Aea. Brief report: treatment of severe colchicine overdose with colchicine-specific Fab fragments. N Engl J Med. 1995;332:642–5.
Ozdemir R, Bayrakci B, Teksam O. Fatal poisoning in children: acute colchicine intoxication and new treatment approaches. Clin Toxicol. 2011;49:739–43.
Tutar HE, Imamoglu A, Atalay S. Recurrent pericarditis in familial Mediterranean fever [letter; comment]. Acta Paediatr. 1999;88:1045–6.
Sadjadi SJ, Moshir M. Treatment of acne vulgaris with colchicine [letter] [see comments]. Acta Derm Venereol. 1998;78:388.
Paydas S. Report on 59 patients with renal amyloidosis. Int Urol Nephrol. 1999;31:619–31.
Yazigi A, Abou-Charaf LC. Colchicine for recurrent pericarditis in children [see comments]. Acta Paediatr. 1998;87:603–4.
Bicer S, Soysal DD, Ctak A, Ucsel R, Karabocuoglu M, Uzel N. Acute colchicine intoxication in a child: a case report. Pediatr Emerg Care. 2007;23:314–7.
Goldbart A, Press J, Sofer S, Kapelushnik J. Near fatal acute colchicine intoxication in a child. A case report. Eur J Pediatr. 2000;159:895–7.
Kilic SC, Alaygut D, Unal E, Koc E, Patiroglu T. Acute colchicine intoxication complicated with extramedullary hematopoiesis due to filgrastim in a child. J Pediatr Hematol Oncol. 2014;36:e460–2.
Carrington CV. The incidence of extravasation of vinca alkaloids supplied in syringes or mini-bags. J Oncol Pharm Pract. 2006;12:113–8.
Crom W, DeGraff S, Synold T, et al. Pharmacokinetics of vincristine in children and adolescents with acute lymphocytic leukemia. J Pediatr. 1994;125:642.
Chan JD. Pharmacokinetic drug interactions of vinca alkaloids: summary of case reports. Pharmacotherapy. 1998;18:1304–7.
Sahenk Z, Brady S, Mendell J. Studies on the pathogenesis of vincristine-induced neuropathy. Muscle Nerve. 1987;10:80–4.
Schlaepfer W. Vincristine-induced axonal alteration in rat peripheral nerve. J Neuropathol Exp Neurol. 1971;30:488–505.
Chae L, Moon H, Kim S. Overdose of vincristine: experience with a patient. J Korean Med Sci. 1998;13:334–8.
Mcleod J, Peny R. Vincristine neuropathy: an electrophysiological and histological study. J Neurol Neurosurg Psychiatry. 1969;32:297.
Suzuki D, Inamoto J, Ohshima J, Cho Y, Saitoh S, Kaneda M, et al. Successful alternative treatment containing vindesine for acute lymphoblastic leukemia with Charcot-Marie-Tooth disease. J Pediatr Hematol Oncol. 2012;34:239–41.
Mahajan S. Acute acoustic nerve palsy associated with vincristine therapy. Cancer. 1981;47:2404.
Dallera F, Gamoletti R, Costa P. Unilateral seizures following vincristine intravenous injection. Tumori. 1984;70:243–4.
Hurwitz RL, Mahoney Jr DH, Armstrong DL, Browder TM. Reversible encephalopathy and seizures as a result of conventional vincristine administration [see comments]. Med Pediatr Oncol. 1988;16:216–9.
Casteels-Van Daele M, Beirinckx J, Baines P. Overdosage with vincristine. J Pediatr. 1977;90:1042–3.
Johnson FL, Bernstein ID, Hartmann JR, Chard Jr RL. Seizures associated with vincristine sulfate therapy. J Pediatr. 1973;82:699–702.
Kaufman I, Dung F, Koenig H, Giammona S. Overdosage with vincristine. J Pediatr. 1976;89:671–4.
Trinkle R, Wu JK. Errors involving pediatric patients receiving chemotherapy: a literature review. Med Pediatr Oncol. 1996;26:344–51.
Suskind R, Brusilow S, Zehr J. Syndrome of inappropriate secretion of antidiuretic hormone produced by vincristine toxicity (with bioassay of ADH level). J Pediatr. 1972;81:90–2.
Meggs W, Hoffman R. Fatality resulting from intraventricular vincristine administration. Clin Toxicol. 1998;36:243–6.
Dorr RT, Alberts DS. Vinca alkaloid skin toxicity: antidote and drug disposition studies in the mouse. J Natl Cancer Inst. 1985;74:113–20.
Conter V, Rabbone ML, Jankovic M, Fraschini D, Corbetta A, Pacheco C, et al. Overdose of vinblastine in a child with Langerhans’ cell histiocytosis: toxicity and salvage therapy [see comments]. Pediatr Hematol Oncol. 1991;8:165–9.
Fiorentino MV, Salvagno L, Chiarion Sileni V, Paccagnella A, Ferrazzi E, Zagonel V, et al. Vindesine overdose [letter]. Cancer Treat Rep. 1982;66:1247–8.
Gutowski MC, Fix DV, Corvalan JR, Johnson DA. Reduction of toxicity of a vinca alkaloid by an anti-vinca alkaloid antibody. Cancer Invest. 1995;13:370–4.
Lotz JP, Chapiro J, Voinea A, Cornu P, Pene F, Bazelly B, et al. Overdosage of vinorelbine in a woman with metastatic non-small-cell lung carcinoma [letter]. Ann Oncol. 1997;8:714–5.
Kouroukis C, Hings I. Respiratory failure following vinorelbine tartrate infusion in a patient with non-small cell lung cancer. Chest. 1997;112:846–8.
Lejonc J, Vernant J, MacQuin I, et al. Myocardial infarction following vinblastine treatment. Lancet. 1980;2:692.
Mandel E, Lewinski U, Djaldetti M. Vincrisine induced myocardial infarction. Cancer. 1975;36:1979–82.
Subar M, Muggia F. Apparent myocardial ischemia associated with vinblastine administration. Cancer Treat Rep. 1986;70:690–1.
Yancey R, Talpaz M. Vindesine-associated angina and ECG changes. Cancer Treat Rep. 1982;66:587–9.
McLendon B, Bron A. Corneal toxicity from vinblastine solution. Br J Ophthalmol. 1978;62:97–9.
Raderer M, Kornek G, Scheithauer W. Re: Vinorelbine-induced pancreatitis: a case report [letter; comment]. J Natl Cancer Inst. 1998;90:329.
Tester W, Forbes W, Leighton J. Vinorelbine-induced pancreatitis: a case report [letter] [see comments]. J Natl Cancer Inst. 1997;89:1631.
Garrett CA, Simpson Jr TA. Syndrome of inappropriate antidiuretic hormone associated with vinorelbine therapy. Ann Pharmacother. 1998;32:1306–9.
Winter S, Arbus G. Syndrome of inappropriate secretion of antidiuretic hormone secondary to vinblastine overdose. CMA J. 1977;117:1134.
Lobert S, Ingram J, Correia J. Additivity of dilantin and vinblastine inhibitory effects on microtubule assembly. Cancer Res. 1999;59:4816–22.
Pierga J, Beuzeboc P, Dorval T, Palangie T, Pouillart P. Favourable outcome after plasmapheresis for vincristine overdose. Lancet. 1992;340:185.
Gale RP. Antineoplastic chemotherapy myelosuppression: mechanisms and new approaches. Exp Hematol. 1985;13:3–7.
Thomas W, Bailony M, Lightsey A, Lew S, Barnet W. Folinic acid rescue in vincristine overdosage in mice. Am J Pediatr Hematol Oncol. 1986;8:266–8.
Jackson D, Wells H, Atkins J, Zekan P, White D, Richards F, et al. Amelioration of vincristine neurotoxicity by glutamic acid. Am J Med. 1988;84:1016–22.
Gilbar PJ, Dooley MJ. Review of case reports of inadvertent intrathecal administration of vincristine: recommendations to reduce occurrence. Asia Pac J Clin Oncol. 2007;3:59–65.
Kawakami K, Kumamoto T, Tonooka S, Abe A, Hayasaka K, Okamoto Y, et al. Severe neurotoxicities in a case of Charcot-Marie-Tooth disease type 2 caused by vincristine for acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2008;30:519–21.
Manelis J, Freundlich E, Ezekiel E, Doron J. Accidental intrathecal vincristine administration. J Neurol. 1982;228:209–13.
Williams ME, Walker AN, Bracikowski JP, Garner L, Wilson KD, Carpenter JT. Ascending myeloencephalopathy due to intrathecal vincristine sulfate: a fatal chemotherapeutic error. Cancer. 1983;51:2041–7.
Gaidys W, Dickerman J, Walters C, Young P. Intrathecal vincristine: report of a fatal case despite CNS washout. Cancer. 1983;52:799–801.
Lau G. Accidental intraventricular vincristine administration: an avoidable iatrogenic death. Med Sci Law. 1996;36:263–5.
al Fawaz IM. Fatal myeloencephalopathy due to intrathecal vincristine administration. Ann Trop Paediatr. 1992;12:339–42.
Zaragoza MR, Ritchey ML, Walter A. Neurourologic consequences of accidental intrathecal vincristine: a case report. Med Pediatr Oncol. 1995;24:61–2.
Dyke R. Treatment of inadvertent intrathecal injection of vincristine. N Engl J Med. 1989;321:1270–1.
Ferayan A, Russell N, Wohaibi M, Awada A, Scherman B. Cerebrospinal fluid lavage in the treatment of inadvertent intrathecal vincristine injection. Child’s Nerv Syst. 1999;15:87–9.
Available from: http://medicine.iupui.edu/clinpharm/ddis/main-table/.
Boman NL, Tron VA, Bally MB, Cullis PR. Vincristine-induced dermal toxicity is significantly reduced when the drug is given in liposomes. Cancer Chemother Pharmacol. 1996;37:351–5.
Boula AM, Mantadakis E, Xilouri IM, Christoforidou AV, Foudoulakis AM, Samonis G. Veno-occlusive disease of the liver associated with chronic myelomonocytic leukemia treated with vincristine and standard doses of cytarabine. Am J Hematol. 2005;79:216–9.
Bisogno G, de Kraker J, Weirich A, Masiero L, Ludwig R, Tournade MF, et al. Veno-occlusive disease of the liver in children treated for Wilms tumor. Med Pediatr Oncol. 1997;29:245–51.
Ichikawa M, Suzuki D, Inamoto J, Ohshima J, Cho Y, Saitoh S, et al. Successful alternative treatment containing vindesine for acute lymphoblastic leukemia with Charcot-Marie-Tooth disease. J Pediatr Hematol Oncol. 2012;34:239–41.
Pascual-Huerta J, Perez-Melero A. Charcot-Marie-Tooth disease and vincristine. J Am Podiatr Med Assoc. 2003;93:229–33.
Shashi V, Selsky C, Morgan E, Kurtzberg J, Bell B, Pediatric Oncology Group S. Vincristine-induced neuropathy as the initial presentation of Charcot-Marie-tooth disease in acute lymphoblastic leukemia: a Pediatric Oncology Group study. J Pediatr Hematol Oncol. 2003;25:316–20.
Ntaios G, Kaiafa G, Girtovitis F, Saouli Z, Kontoninas Z, Diamantidis MD, et al. Veno-occlusive disease of the liver during induction therapy for acute lymphoblastic leukemia. Int J Hematol. 2008;88:441–2.
Bermudez M, Fuster JL, Llinares E, Galera A, Gonzalez C. Itraconazole-related increased vincristine neurotoxicity: case report and review of literature. J Pediatr Hematol Oncol. 2005;27:389–92.
Brumen V, Horvat D. Work environment influence on cytostatics-induced genotoxicity in oncologic nurses. Am J Ind Med. 1996;30:67–71.
Cave TA, Norman P, Mellor D. Cytotoxic drug use in treatment of dogs and cats with cancer by UK veterinary practices (2003 to 2004). J Small Anim Pract. 2007;48:371–7.
Hamscher G, Mohring SA, Knobloch A, Eberle N, Nau H, Nolte I, et al. Determination of drug residues in urine of dogs receiving anti-cancer chemotherapy by liquid chromatography-electrospray ionization- tandem mass spectrometry: is there an environmental or occupational risk? J Anal Toxicol. 2010;34:142–8.
Kusnetz E, Condon M. Acute effects from occupational exposure to antineoplastic drugs in a para-professional health care worker. Am J Ind Med. 2003;44:107–9.
Tron VA, Bally MB, Cullis PR. Vincristine-induced dermal toxicity is significantly reduced when the drug is given in liposomes. Cancer Chemother Pharmacol. 1996;37:351–5.
Chui FC. Podophyllotoxin and related compounds. In: Herbert H, Schumburg PSS, editors. Experimental and clinical neurotoxicology. 2nd ed. New York: Oxford University Press; 2000. p. 1008–10.
Stahelin HF, Von Wartburg A. The chemical and biological route from podophyllotoxin glucoside to etoposide: Ninth Cain memorial award lecture. Cancer Res. 1991;51:5–15.
Vogelzang NJ, Raghavan D, Kennedy BJ. VP-16-213 (Etoposide): The Mandrake Root from Issyk-Kul. Am J Med. 1982;72:136–44.
Stewart CF, Ratain MJ. Topoisomerase interactive agents. In: Vincent TDJHS, editor. Cancer – principle and practice of oncology, vol. 1. 5th ed. Philadelphia: Lippincott-Raven; 1997. p. 452–67.
Campbell AN. Accidental poisoning with podophyllum. Lancet. 1980;1:206–7.
Cassidy DE, Drewry J, Fanning JP. Podophyllum toxicity: a report of a fatal case and a review of the literature. J Toxicol – Clin Toxicol. 1982;19:35–44.
Chamberlain MJ, Reynolds AL, Yeoman WB. Medical memoranda. Toxic effect of podophyllum application in pregnancy. Br Med J. 1972;3:391–2.
Clark ANG, Parsonage MJ. A case of podophyllum poisoning with involvement of the central nervous system. BMJ. 1957;2:1155–7.
Coruh M, Argun G. Podophyllin poisoning. A case report. Turk J Pediatr. 1965;7:100–3.
McFarland MF, McFarland J. Accidental ingestion of Podophyllum. Clin Toxicol. 1981;18:973–7.
Montaldi DH, Giambrone JP, Courey NG, Taefi P. Podophyllin poisoning associated with the treatment of condylomata acuminatum: a case report. Am J Obstet Gynecol. 1974;119:1130–1.
Rate RG, Leche J, Chervenak C. Podophyllin toxicity. Ann Intern Med. 1979;90:723.
Slater GE, Rumack BH, Peterson RG. Podophyllin poisoning: systemic toxicity following cutaneous application. Obstet Gynecol. 1978;52:94–6.
West WM, Ridgeway NA, Morris AJ, Sides PJ. Fatal Podophyllin ingestion. South Med J. 1982;75:1269–70.
Frasca T, Brett AS, Yoo SD. Mandrake toxicity. A case of mistaken identity. Arch Intern Med. 1997;157:2007–9.
Chang MH, Liao KK, Wu ZA, Liao KK. Reversible myeloneuropathy resulting from podophyllin intoxication: an electrophysiological follow up. J Neurol Neurosurg Psychiatry. 1992;55:235–6.
Chu CC, Huang CC, Chu NS. Sensory Neuropathy due to Bajiaolian (podophyllotoxin) intoxication. Eur Neurol. 2000;44:121–3.
Dobb GJ, Edis RH. Coma and neuropathy after ingestion of herbal laxative containing podophyllin. Med J Aust. 1984;140:495–6.
Ng TH, Chan YW, Yu YL, Chang CM, Ho HC, Leung SY, et al. Encephalopathy and neuropathy following ingestion of a Chinese herbal broth containing podophyllin. J Neurol Sci. 1991;101:107–13.
Anonymous. Podofilox for genital warts. Med Lett Drugs Ther. 1991;33:117–8.
Bonnez W, Elswick Jr RK, Bailey-Farchione A, Hallahan D, Bell R, Isenberg R, et al. Efficacy and safety of 0.5 % podofilox solution in the treatment and suppression of anogenital warts. Am J Med. 1994;96:420–5.
Gowdey G, Lee RK, Carpenter WM. Treatment of HIV-related hairy leukoplakia with podophyllum resin 25 % solution. Oral Surg Oral Med Oral Pathol Oral Radiol Endodont. 1995;79:64/7.
Anonymous. Podophyllotoxin derivatives. In: Kastrup E, editor. Drug facts and comparisons. St Louis: Wolters & Kluwer; 2000. p. 1879–81.
Arnold AM, Whitehouse JM. Etoposide: a new anti-cancer agent. Lancet. 1981;2:912–5.
Donehower R, Rowinsky E. DNA Topoisomerase II Inhibitors. In: Perry MC, editor. Chemotherapy source book. 2nd ed. Baltimore: William & Wilkins; 1996. p. 434–45.
Anonymous. Condylox Gel 0.5 %. In: Murray L, editor. Physician’s desk reference. 55th ed. Montvale: Medical Economics; 2001. p. 2248–9.
Stoehr GP, Peterson AL, Taylor WJ. Systemic complications of local podophyllin therapy. Ann Intern Med. 1978;89:362–3.
Anonymous. Cavinton, injection, tablet. Geographia Medica. 1984;14:361–3.
Hoffe PA. Cell cycle, mitosis, and meiosis. Medical molecular genetics. Madison: Fence Creek Publishing; 1998. p. 92–102.
Loike JD, Horowitz SB. Effects of Podophyllotoxin and VP-16-213 on microtubule assembly in vitro and nucleoside transport in HeLa cells. Biochemistry. 1976;15:5434–43.
Filley CM, Graff-Radford NR, Lacy JR, Heitner MA, Earnest MP. Neurologic manifestations of podophyllin toxicity. Neurology. 1982;32:308–11.
Grieder A, Maurer R, Stahelin H. Effect of an epipodophyllotoxin derivative (VP 16–213) on macromolecular synthesis and mitosis in mastocytoma cells in vitro. Cancer Res. 1974;34:1788–93.
Krishan A. Cytofluorometric studies on the action of podophyllotoxin and epipodophyllotoxins (VM-26, VP-16-213) on the cell cycle traverse of human lymphoblasts. J Cell Biol. 1975;66:521–30.
Laprevote-Heully MC, Lambert H, Larcan A. Letter: syncope due to arrhythmia. Role of vincamine apropos of 3 observations. Nouv Presse Med. 1974;3:825.
Grieder A, Maurer R, Stahelin H. Comparative study of early effects of epipodophyllotoxin derivatives and other cytostatic agents on mastocytoma cultures. Cancer Res. 1977;37:2998–3005.
Loike JD, Brewer CF, Sternlicht H, Gensler WJ, Horowitz SB. Structure activity study of the inhibition of microtubule assembly in vitro by podophyllotoxin and its congeners. Cancer Res. 1978;38:2688–93.
Kalwinsky DK, Look AT, Ducore J, Fridland A. Effects of the epipodophyllotoxin VP 16-213 on cell cycle traverse, DNA synthesis, and DNA strand size in cultures of human leukemic lymphoblasts. Cancer Res. 1983;43:1592–7.
Long BH, Minocha A. Inhibition of topoisomerase II by VP-16-213 (etoposide), VM-26 (teniposide), and structural congeners as an explanation for in vivo DNA breakage and cytotoxicity. Proc Am Assoc Cancer Res. 1983;24:321.
Cao B, Chen H, Gao Y, Niu C, Zhang Y, Li L. CIP-36, a novel topoisomerase II-targeting agent, induces the apoptosis of multidrug-resistant cancer cells in vitro. Int J Mol Med. 2015;35:771–6. Epub 2015/01/17. eng.
Chen H, Wang J, Zhang J, Wang Y, Cao B, Bai S, et al. L1EPO, a novel podophyllotoxin derivative overcomes P-glycoprotein-mediated multidrug resistance in K562/A02 cell line. Biol Pharm Bull. 2009;32:609–13. Epub 2009/04/02. eng.
Kumar A, Kumar V, Alegria AE, Malhotra SV. Synthetic and application perspectives of azapodophyllotoxins: alternative scaffolds of podophyllotoxin. Curr Med Chem. 2011;18:3853–70. Pubmed Central PMCID: Pmc3278234, Epub 2011/08/10. eng.
Liu YQ, Tian J, Qian K, Zhao XB, Morris-Natschke SL, Yang L, et al. Recent progress on C-4-modified podophyllotoxin analogs as potent antitumor agents. Med Res Rev. 2015;35:1–62. Pubmed Central PMCID: Pmc4337794, Epub 2014/05/16. eng.
O’Dwyer PJ, Leyland-Jones B, Alonso MT, Marsoni S, Wittes RE. Etoposide (VP-16-213). Current status of an active anticancer drug. N Engl J Med. 1985;312:692–700.
Hawkins MM. Secondary leukaemia after epipodophyllotoxins [letter; comment]. Lancet. 1991;338:1408.
Kumar L. Epipodophyllotoxins and secondary leukaemia. Lancet. 1993;342:819–20.
Habibi B, Baumelou A, Seradaru M. Acute intravascular haemolysis and renal failure due to teniposide related antibody [letter]. Lancet. 1981;1:1423–4.
McLeod HL, Baker DK, Pui C, Rodman JH. Somnolence, hypotension, and metabolic acidosis following high dose teniposide treatment in children with leukemia. Cancer Chemother Pharmacol. 1991;29:150.
Imrie KR, Couture F, Turner CC, Sutcliffe SB, Keating A. Peripheral neuropathy following high-dose etoposide and autologous bone marrow transplantation. Bone Marrow Transplant. 1994;13:77–9.
Thant M, Hawley RJ, Smith MT, Cohen MH, Minna JD, Bunn PA, et al. Possible enhancement of vincristine neuropathy by VP-16. Cancer. 1982;49:859–64.
Leff RS, Thompson JM, Daly MB, Johnson DB, Harden EL, Mercier RJ, et al. Acute neurologic dysfunction after high dose etoposide therapy for malignant glioma. Cancer. 1988;62:32–5.
Pawlicki M, Zuchowska-Vogelgesang B, Sliz E. The case of Vepesid overdosage in a patient with Hodgkin’s disease. Cancer Chemother Pharmacol. 1990;25:387.
Pommier Y, Leo E, Zhang H, Marchand C. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol. 2010;17:421–33. Epub 2010/06/11. eng.
Dudley WH. Fatal podophyllin poisoning. Med Rec. 1890;37:409.
Gorin F, Kindall D, Seyal M. Dorsal radiculopathy resulting from podophyllin toxicity. Neurology. 1989;39:607–8.
Heath A, Mellstrand T, Ahlmen J. Treatment of podophyllin poisoning with resin hemoperfusion. Hum Toxicol. 1982;1:373–8.
Kumar M, Shanmugham A, Prabha S, Adhisivam B, Narayanan P, Biswal N. Permanent neurological sequelae following accidental podophyllin ingestion. J Child Neurol. 2012;27:209–10. Epub 2011/09/14. eng.
Oliveira AS, Calia LC, Kiyomoto BH, Povoa EF, Schmidt B, Gabbai AA. Acute necrotizing myopathy and podophyllin toxicity. Arq Neuropsiquiatr. 1996;54:288–92.
Moher LM, Maurer SA. Podophyllum toxicity: case report and literature review. J Fam Pract. 1979;9:237.
Ward JW, Clifford WS, Monaco AR, Bickerstaff HS. Fatal systemic poisoning following podophyllin treatment of condyloma acuminatum. South Med J. 1954;47:1204–6.
Tomczak RL, Hake DH. Near fatal systemic toxicity from local injection of podophyllin for pedal verrucae treatment. J Foot Surg. 1992;31:36–42.
Freeman MC, Weimer LH, Arnaudo E, Brust JCM. Neuropathic and autonomic effects of intramuscular podophyllin. Ann Neurol. 1997;42:416.
Conard PF, Hanna N, Rosenblum M, Gross JB. Delayed recognition of podophyllum toxicity in a patient receiving epidural morphine [see comments]. Anesth Analg. 1990;71:191–3.
Chang MH, Lin KP, Wu ZA, Liao KK. Acute ataxic sensory neuropathy resulting from podophyllin intoxication. Muscle Nerve. 1992;15:513–4.
Cabrera Rodriguez J, Munoz GJ. Acute pain due to vinorelbine. Rev Clin Esp. 1998;198:514–6.
O’Mahony S, Keohane C, Jacobs J, O’Riordan D, Whelton M. Neuropathy due to podophyllin intoxication. J Neurol. 1990;237:110–2.
Chan YW. Magnetic resonance imaging in toxic encephalopathy due to podophyllin poisoning. Neuroradiology. 1991;33:372–3.
Leslie KO, Shitamoto B. The bone marrow in systemic podophyllin toxicity. Am J Clin Pathol. 1982;77:478–80.
Bernstein SH, Fay JP, Christiansen NP, Pinero L, Shah D, Stephan M, et al. Sequential interleukin-3 and granulocyte-colony stimulating factor prior to and following high-dose etoposide and cyclophosphamide: a phase I/II trial. Clin Cancer Res. 1997;3(9):1519–26.
Gianni AM, Bregni M, Siena S, Magni M, Di Nicola M, Lombardi F, et al. Granulocyte-macrophage colony-stimulating factor or granulocyte colony-stimulating factor infusion makes high-dose etoposide a safe outpatient regimen that is effective in lymphoma and myeloma patients. J Clin Oncol. 1992;10(12):1955–62.
Jakacki RI, Jamison C, Heifetz SA, Caldemeyer K, Hanna M, Sender L. Feasibility of sequential high-dose chemotherapy and peripheral blood stem cell support for pediatric central nervous system malignancies. Med Pediatr Oncol. 1997;29(6):553–9.
Maslak PG, Weiss MA, Berman E, Yao TJ, Tyson D, Golde DW, et al. Granulocyte colony-stimulating factor following chemotherapy in elderly patients with newly diagnosed acute myelogenous leukemia. Leukemia. 1996;10(1):32–9.
Neill HB, Miller AA, Clamon GH, Perry MC, Crawford J, Green MR. A phase II study evaluating the efficacy of carboplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in patients with stage IIIB and IV non-small cell lung cancer and extensive small cell lung cancer. Semin Oncol. 1997;24(4 Suppl 12):S12-130–4.
Weaver CH, Schwartzberg LS, Birch R, Greco FA, Rhinehart S, Hainsworth J, et al. Collection of peripheral blood progenitor cells after the administration of cyclophosphamide, etoposide, and granulocyte-colony-stimulating factor: an analysis of 497 patients. Transfusion. 1997;37(9):896–903.
Karol MD, Conner CS, Murphrey KJ. Podophyllum: suspected teratogenicity from topical application. Clin Toxicol. 1980;16:283–6.
Rosenstein G, Rosenstein H, Freeman M, Weston N. Podophyllum-a dangerous laxative. Pediatrics. 1976;57:419–21.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Grading System for Levels of Evidence Supporting Recommendations in Critical Care Toxicology, 2nd Edition
-
I
Evidence obtained from at least one properly randomized controlled trial.
-
II-1
Evidence obtained from well-designed controlled trials without randomization.
-
II-2
Evidence obtained from well-designed cohort or case-control analytic studies, preferably from more than one center or research group.
-
II-3
Evidence obtained from multiple time series with or without the intervention. Dramatic results in uncontrolled experiments (such as the results of the introduction of penicillin treatment in the 1940s) could also be regarded as this type of evidence.
-
III
Opinions of respected authorities, based on clinical experience, descriptive studies and case reports, or reports of expert committees.
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this entry
Cite this entry
Snow, J., Kao, L., Furbee, R. (2016). Antitubulin Agents: Colchicine, Vinca Alkaloids, and Podophyllin. In: Brent, J., Burkhart, K., Dargan, P., Hatten, B., Megarbane, B., Palmer, R. (eds) Critical Care Toxicology. Springer, Cham. https://doi.org/10.1007/978-3-319-20790-2_138-1
Download citation
DOI: https://doi.org/10.1007/978-3-319-20790-2_138-1
Received:
Accepted:
Published:
Publisher Name: Springer, Cham
Online ISBN: 978-3-319-20790-2
eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences